However, mosaic FGFR2 alterations have been linked to a number of neoplasms including colon, breast, gastric, endometrial, esophageal and cholangiocarcinoma (Hansen et al. 2005; Kunii et al. 2008; Zhang et al. 2009; Reintjes et al. 2013; Mathur et al. 2014; Kwak et al. 2015; Helsten et al. 2016; Smyth et al. 2017; Shi et al. 2018). This evidence concerns the gene FGFR2 and cholangiocarcinoma.